#drug development

Revolution Medicines has started shipping an experimental pancreatic cancer drug, and its CEO says an FDA submission is coming soon.

Even with limited details in the supplied text, the release of regular ASCO abstracts appears to have focused attention on several contested oncology areas, underscoring how conference data now drives pharmaceutical deal

Biogen and Denali Therapeutics are dropping their LRRK2 inhibitor program in certain patients with non-genetic Parkinson’s disease after the drug failed a Phase 2b study in early Parkinson’s.

Novartis says it is looking to apply Avidity Biosciences’ underlying science beyond muscular dystrophies as it works to realize more value from its $12 billion acquisition.

A Georgia State-led team reports that an oral drug candidate, GHP-88310, suppressed orthoparamyxovirus infections in animal models, offering a potential route toward treatments for measles, croup-linked viruses and other

Daiichi Sankyo said it is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an extraordinary loss of 149.4 billion yen after overestimating demand, highlighting the risks of expanding

Researchers at Helmholtz Munich have built a hybrid obesity therapy that uses GLP-1 and GIP signaling to deliver a second metabolic drug into target cells, producing stronger weight-loss and glucose effects in mice.

Entrada Therapeutics’ next-generation Duchenne muscular dystrophy candidate disappointed in an early study, a setback in a competitive race to improve exon-skipping drugs.

The latest annual survey of Alzheimer’s drug development finds a larger and more diverse clinical pipeline, with more trials, more therapeutic approaches, and a declining share of amyloid-targeted programs.

A Karolinska Institutet study found that daily low-dose endoxifen reduced mammographic breast density by 19% to 26% in healthy premenopausal women over six months, with fewer side effects than standard tamoxifen.

Three biotech IPOs priced with more than $850 million combined as Avalyn surged in its Nasdaq debut, offering an early signal of renewed investor appetite for the sector.

After years of limited treatment options, kidney disease research is moving into a more active phase, with targeted therapies ranging from immunomodulators to genetically defined drugs.

A new Cell study identifies a specific subset of opioid receptors on prefrontal cortex interneurons as a key part of ketamine’s rapid antidepressant action, opening the door to more targeted therapies.

A study in Immunity points to malfunctioning natural killer cells, not macrophages alone, as a key driver of mevalonate kinase deficiency, opening a possible path toward JAK inhibitor treatment.

Researchers at Helmholtz Munich report a new treatment concept that combines GLP-1 and GIP signaling in a single hybrid molecule, with the goal of addressing obesity and type 2 diabetes together.

A new FDA effort aims to use AI and real-time monitoring to reduce delays between clinical trial phases and compress parts of the drug development timeline.

The FDA has launched a pilot to review clinical trial data as it is generated, giving agency scientists earlier access to information from ongoing studies.

Roche says its investigational breast cancer pill giredestrant could still become a major product, with CEO Thomas Schinecker arguing it may one day outsell Herceptin despite an earlier first-line trial failure.

A pancreatic cancer drug candidate from Revolution Medicines, daraxonrasib, is being described as one of the most promising developments in decades, with early signs of unusually strong results against a target long seen

A new review says anti-amyloid Alzheimer's treatments are unlikely to deliver clinically meaningful benefits and may raise the risk of brain bleeding and swelling, reopening debate over one of medicine's most contested R